3 results
The primary objective of this study is to demonstrate the efficacy of the combination therapy of aliskiren (150 mg and 300 mg) and HCTZ 25 mg in hypertensive patients who do not show sufficient blood pressure response to a 4-week treatment of HCTZ…
1. Primary objectiveThe identification and discrimination of AF burden and the patient burden of the nECG system in patients with paroxysmal AF undergoing catheter ablation for AF.2. Secondary objectiveAssess the relation between the changes in…
To evaluate the proportion of patients indicating an overall preference via a Patient Preference Questionnaire (PPQ) for either the subcutaneous (SC) or the intravenous (IV) route of rituximab administration.